Symbiosis Pharmaceutical unveils new freeze-drying service for pharma industry

Symbiosis Pharmaceutical Services, a small CMO located in Scotland, said it is offering a new bulk lyophilisation (freeze-drying) service after getting new contracts from the pharmaceutical industry.

The Sterling, Scotland-based company will use the process to support clients in the U.S., Europe and Asia to assist in the manufacturing of bulk intermediates and APIs by lyophilisation, Symbiosis said in a press release.

Though lyophilisation has been used at its facility before, the company now offers the ability to provide both aseptic and low bioburden clean room dispensing of bulk materials.

Symbiosis CEO Colin MacKay

"This service launch has very much been driven by market demand from biotech and pharmaceutical companies requiring either a one-off batch or the ongoing bulk lyophilisation of APIR or finished products," Colin MacKay, the company's CEO, said in a statement.

Symbiosis was among a number of other companies to open biologics plants in 2012 when Belgian drugmaker UCB Pharma completed an $84.8 million plant to manufacture products it had been outsourcing. Eisai subsidiary Morphotek earlier that year opened an $80 million plant in Exton, PA, that could produce multiple biologics simultaneously.

- check out the release

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.